This Phase IIA study is designed to evaluate the safety and efficacy of Oramed’s oral insulin capsule on Type II diabetic volunteers. This study is slated to begin in the second quarter of 2008. The trials are expected to last several months.
Nadav Kidron, CEO of Oramed, said: “Oramed’s oral insulin aims to revolutionize the current methods of treating diabetes.”